Aspen forecasts half-year results ahead of estimate on restart of heparin sale
Share:
(Reuters) - South Africa's Aspen Pharmacare Holdings Ltd said on Friday it expects to report half-year results slightly above its forecast as the drugmaker's manufacturing unit benefited from the restart of heparin sales to third party customers. Revenue is expected to grow between 2% and 4% for the six months ended Dec. 31, the company said in a statement.The nearly 170-year-old drug maker, with a presence in about 56 countries, had said in September that it would pursue supplying heparin..